A-eyedrops on Ocular Alignment and Binocular Vision
NCT05379855 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 339
Last updated 2025-02-25
Summary
Atropine is a non-selective muscarinic acetylcholine (M) receptor antagonist that paralyzes the ciliary muscle, dilates the pupil, and reduces the power of accommodation. Current studies have confirmed the effect of low concentrations of atropine drops in slowing the progression of myopia. In the atropine treatment for myopia (ATOM2) study, there was a rapid and dose-dependent decrease in accommodation after atropine drops: after 2 weeks of use, accommodation decreased from baseline 16.2D to 11.3D (4.9D) in the 0.01% atropine drops group, from baseline 16.7D to 3.8D (12.9D) in the 0.1% atropine group, and from baseline 15.8 D to 2.2 D (13.6 D) in the 0.5% atropine group; one year after withdrawal, there was some recovery of the accommodation in all the three groups, but it was still lower than the baseline values for each group, with a mean decrease of 2.56 D.Similar results were found in the Low-concentration Atropine for Myopia Progression (LAMP) Study by Janson C. Yam, 0.05% atropine drops reduced the accommodation by approximately 2D on average after 1 year of treatment.
In general, if accommodation decreases by 2D or more compared to normal values, accommodation insufficiency is considered. There is a linkage between accommodation and convergence called accommodative convergence-to-accommodation (AC/A) which is closely related to exotropia. It was reported that the amount of accommodation required to maintain binocular fusion in patients with intermittent exotropia was greater than that of normal controls. In addition, pupil size and visual acuity are also factors that affect accommodation. In summary, the reduced accommodation amplitude, pupil dilation, and blurred near vision caused by atropine drops would affect the progression of intermittent exotropia and the ocular alignment after the surgery. In most cases, the reduced accommodation and convergence might induce exotropia, but in some patients, they may use more accommodative stimuli to compensate the insufficiency of accommodation, and there may be an increase in convergence or even esotropia.
Taken together, due to the effect of atropine drops on pupil size, near visual acuity, and accommodation amplitude, the investigators hypothesize that atropine drops are likely to affect binocular vision and ocular alignment in patients with exotropia and exophoria.
Conditions
- Exotropia
- Exophoria
- Myopia
Interventions
- DRUG
-
0.01% atropine eye drops
using 0.01% atropine eye drops for both eyes every night
- DRUG
-
placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)
using placebo eye drops (0.1% sodium hyaluronate ophthalmic solution) for both eyes every night
- DRUG
-
0.05% atropine eye drops
using 0.05% atropine eye drops for both eyes every night
Sponsors & Collaborators
-
Eye & ENT Hospital of Fudan University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 5 Years
- Max Age
- 14 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-02
- Primary Completion
- 2027-02-01
- Completion
- 2027-02-01
Countries
- China
Study Locations
More Related Trials
-
Efficacy and Safety of 1% Atropine "5+3" Regimen in Children and Adolescents Controlling Myopia
NCT05448989 ·Status: UNKNOWN ·Phase: PHASE4
-
Low-Dose Atropine for Treatment of Myopia
NCT03334253 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Low-concentration Atropine for Myopia Control in Chinese Children and Adolescents
NCT05597163 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Low-dose Atropine for Myopia Control in Children
NCT03865160 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control
NCT02055378 ·Status: COMPLETED ·Phase: NA
-
Study on the Effect of Two Ways of Cycloplegia on Biological Parameters of Ciliary Muscle
NCT05449015 ·Status: UNKNOWN ·Phase: PHASE4
-
Atropine for Children and Adolescent Myopia Progression Study
NCT03949101 ·Status: UNKNOWN ·Phase: PHASE4
-
The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)
NCT03140358 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Atropine 0.01% Eye Drops in Myopia Study
NCT03508817 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
NCT06209320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center
NCT07164092 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children
NCT00371124 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops
NCT06209281 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy Comparison of 2 Low-dose Atropine Eye Drops in Vietnamese Children Myopia Management
NCT05803863 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Trial Comparing Daily Atropine Versus Weekend Atropine
NCT00094614 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of 0.01% Atropine Sulfate Solution in Controlling of Myopia Progression in Children
NCT04338373 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effectiveness and Safety of Two Low-concentration Atropine Sulfate Eye Drops (0.01%/0.02%) for Delaying the Pediatric Myopia Progression
NCT06708156 ·Status: RECRUITING ·Phase: PHASE3
-
Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate
NCT03374306 ·Status: COMPLETED ·Phase: NA
-
A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control
NCT07095894 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Effects of Low Concentration Atropine on Pupillary Size and Accommodative Amplitude
NCT03699423 ·Status: COMPLETED ·Phase: PHASE1
-
Topical 0.01% Atropine for the Control of Fast Progressing Myopia
NCT04173780 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
The Influence of Atropine on Choroidal Thickness
NCT03158142 ·Status: COMPLETED ·Phase: PHASE4
-
Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old
NCT00315302 ·Status: COMPLETED ·Phase: PHASE3
-
Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control
NCT06523504 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia
NCT00000170 ·Status: COMPLETED ·Phase: PHASE3